<?xml version="1.0" encoding="UTF-8"?>
<p>Bufadienolides constitute a subfamily within cardiac glycosides family of secondary metabolites and they are considered polyhydroxy C-24 steroids, presenting an α-pyrone ring at the C-17β position (
 <xref ref-type="fig" rid="pharmaceuticals-13-00444-f002">Figure 2</xref>) [
 <xref rid="B113-pharmaceuticals-13-00444" ref-type="bibr">113</xref>]. Bufadienolides presence in 
 <italic>Bryophyllum</italic> species is genotype and organ dependent [
 <xref rid="B68-pharmaceuticals-13-00444" ref-type="bibr">68</xref>], being four species the most representative sources of these compounds: 
 <italic>B. daigremontianum</italic>, 
 <italic>B. × houghtonii</italic>, 
 <italic>B. tubiflorum,</italic> and 
 <italic>B. pinnatum</italic> (
 <xref rid="pharmaceuticals-13-00444-t004" ref-type="table">Table 4</xref>). Universally-distributed bufadienolides, such as bersaldegenin and bryophyllin derivatives [
 <xref rid="B77-pharmaceuticals-13-00444" ref-type="bibr">77</xref>,
 <xref rid="B114-pharmaceuticals-13-00444" ref-type="bibr">114</xref>], can be found together with genotype-specific compounds, such as kalanchosides [
 <xref rid="B115-pharmaceuticals-13-00444" ref-type="bibr">115</xref>] and kalanhybrins [
 <xref rid="B71-pharmaceuticals-13-00444" ref-type="bibr">71</xref>].
</p>
